Nanomedicine and Nanoscale Delivery (Focus Group - NND)
Currently, commercials available LAI products containing leuprorelin of Leuplin® Inj. (FDA product name: Lupron Depot®) and Eligard® Inj. are inconvenient to administer and involve complex manufacturing processes. Therefore, we have developed a novel formulation of leuprorelin injection that is simple to manufacturing process and provides sustained release for one month. The pharmacokinetic results showing sustained drug release for one month in guinea pigs were confirmed and clinical trials were conducted to evaluate pharmacokinetic and pharmacodynamic results.